Abstract:Objective To investigate the effect of Irbesartan combined with Amiodarone in the treament of heart failure combined with arrhythmia. Methods Sixty cases of patients with heart failure and arrhythmia treated in our hospital from January 2017 to January 2019 were selected for retrospective study. According to the treatment methods, the patients were divided into control group (30 cases) and observation group (30 cases). The control group was treated with Amiodarone, while the observation group was treated with Amiodarone combined with Irbesartan. The clinical efficacy,cardiac function indicators, heart rate turbulence indicators and total incidence of adverse reactions were compared between the two groups. Results The total clinical effective rate of the observation group was 93.33%, which was higher than 73.33% of the control group, the difference was statistically significant (P<0.05). After treatment, the left ventricular ejection fraction and stroke output of the observation group were higher than those of the control group, and the Nterminal brain natriuretic (NT-proBNP) level of the observation group was lower than that of the control group, the differences were statistically significant (P<0.05). After treatment, the initial value of oscillation (TO), oscillation slope(TS), time-domain value of heart rate variability (SDNN) in the observation group were higher than those in the control group, the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of Irbesartan and Amiodarone can improve the heart function and heart rate of patients with heart failure and arrhythmia more effectively, the curative effect is remarkable, the safety is good.
李丽曼;杨专青. 厄贝沙坦联合胺碘酮治疗心力衰竭合并心律失常的效果[J]. 中国当代医药, 2020, 27(6): 156-159.
LI Li-man ;YANG Zhuan-qing. Effect of Irbesartan combined with Amiodarone in the treament of heart failure complicated with arrhythmia. 中国当代医药, 2020, 27(6): 156-159.